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 Abstract 
Paraneoplastic neurologic disorders can affect any part of the nervous 
system. Rarely, the motor neuron or motor axons may be affected in 
patients with cancer , leading to clinical signs and symptoms that 
resemble ALS.  Myasthenia gravis (MG) is the prototypic 
autoimmune disorder of the nervous system. In most cases ,MG is an 
idiopathic disorder, and the events leading to the production of 
acetylcholine receptor autoantibodies are not known. About 15% of 
the patients have a paraneoplastic form of MG associated with a 
thymic neoplasm ( thymoma ).Patients with paraneplastic MG  
typically have late-onset  generalized MG and require long –term 
immunosuppression. Another form of neuromuscular junction 
disorder , the Lambert- Eaton myasthenic syndrome, often occurs a 
as a paraneoplastic manifestation of small cell lung cancer. Together, 
MG and Lambert-Eaton syndrome are the most common 
paraneoplastic neurologic disorders. 
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Introduction: 
  Paraneoplastic neurologic disorders are diseases of nervous system 
that occur in association with cancer but are not due to direct effects 
of the tumor or its metastases. These disorders are causes by remote 
effects of malignancy believed to be mediated by immune system. 
The mechanism likely involves the expression of antigens by the 
tumor that stimulates an immune response involving T cells , 
antibodies, or both, that is directed against not only tumor cells but 
also neutral or nerve/muscle cells. 
   An association of MG with thymic tumor first was reported in 1903 
(Laquer,1903)(1). As many as 40% to 50% of patients with thymoma 
have MG, and approximately 15% of patients with MG have 
thymoma (Thomas CR,1999)(2). MG is caused by autoantibodies 
  Абстракт 
Паранеопластичните 
невролошки пореметувања 
можат да го зафатат било 
кој дел од невролошкиот 
систем. Ретко кога 
моторниот неврон или 
моторните аксони можат да 
бидат афектирани кај 
пациенти со канцер,но сепак 
доколку се зафатат води до 
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Амиотрофична латерална 
склероза. Друго заболување кое 
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заболување на нервниот 
систем е Myasthenia gravis. Во 
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етиологијата е идиопатска и 
начините за продукција на 
автоантителата за 
ацетилхолинските рецептори 
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Myasthenia gravis асоцирана со 
тимом. Пациентите обично 
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со доцен почеток и истите 
бараат долгогодишен 
третман со имуносупресија. 
Друга форма на нарушување 
на невромускулната синапса е 
Sy. Lambert – Eaton, што често 
е придружен со 
ситноклеточниот карцином 
на белите дробови. 
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against postsynaptic nicotinic acetylcholine receptors ( AChRs)  at neuromuscular junction 
(Willcox,1993)(3). The resulting deficit in neuromuscular transmission results in the 
characteristic symptoms of weakness and fatique  of bulbar and proximal muscles.  
   Paraneoplastic MG is clinically identical to MG without thymoma with few exceptions. The 
majority of patients with thymoma are older than 50 years, with a mean age of 55. However, 
thymoma may be found in myasthenic patients as young as 20 years and rarely in childhood 
MG.  
The female predominance seen in younger patients with MG is not evident in paraneoplastic 
or thymomatous MG. The symptoms of myasthenia are typically generalized, may have a 
more rapid onset, and may be difficult to control until the thymoma is removed. After 
appropriate thymoma treatment , contemporary studies indicate that the prognosis of 
paraneoplastic MG is similar to other cases of late-onset similar to other cases of late-onset, 
nontymomatous MG ( Bril et al,1998,de Perrot et al ,2002)(4) . 
  Thymoma is a relatively rare neoplasm of thymic epithelial cells, which is unique because 
of its frequent association with autoimmunity , probably due to dysregulation of lymphocyte 
selection ( Morgenthaler et al, 1993)(5). Thymoma-related autoimmunity also may be caused 
by presentation of self -antigens expressed by the neoplastic cell. Autoractive T lymphocytes 
may proliferate , leave the tumor, and stimulate B cells for antibody production. Unlike the 
case for tymic hyperplasia, no significant autoantibody production occurs within the tymus 
itself. Other tumors that originate in the anterior mediastinum (lymphoma, carcinoid) do not 
demonstrate the same association with autoimmunity. 
Antibody profiles in Paraneoplastic Myasthenia Gravis 
Autoantibodies specific for skeletal muscle AChR, striated muscle antigens as well as 
neuronal antigens , are common in patients with thymoma and may be found even in absence 
of clinical evidence of MG (Vernino and Lennon, 2004)(6). Muscle AChR antibodies are the 
most commonly detected antibodies with thymoma. In most studies , all patients with 
thymoma and MG have muscle AChR binding antibodies (Lindstrom et al,1998)(7). In other 
words, thymoma is associated with neither seronegative MG nor musclr- specific receptor 
tyrosine kinase ( MuSK) antibodies (Leite et al, 2005)(8). AChr modulating antibodies cause 
a reduction in surface AChr, and blocking antibodies are those those that interfere with the 
acetylcholine) AChR modulating antibody levels are generally high in patients with 
thymoma. 
Striational antibodies were the first autoantibodies recognized with thymoma and 
MG. These antibodies recognize muscle cytoplasmic proteins, including titin, myosin, actin 
alpha-actinin. Striational antibodies are detected in a majority of patients - 85% with 
thymomatous MG and also in a minority of thymoma patients without MG (Somnier and 
Engel,2002)(9). Other antibodies that can be found are  against glutamic acid decarboxylase 
(GAD65),collapsing-response mediator protein (CRMP5),voltage-gated potassium channels 
(VGKCs),antinuclear antibodies ,antimitochondrial antibodies and others. 
 
 
  
Motive and Purpose: 
  Timely treatment of patients with Myasthenia gravis which is associated with thymoma 
improves the quality of life, reduce complications , reduces morbidity on the one hand and 
prolongs survival time of the other. 
  The purpose of the cases is to see the connection of Myasthenia gravis with thymoma as 
often paraneoplastic neurological disease. 
    
Material and Methods: The study is a review of two cases (case report): 
 
First case: 
 Patient 32 years old, female, unemployed. 
 The disease began in June 2009 with progressive bilateral symmetrical ptosis, 
diplopia in horizontal view left and right, dysarthria and proximal muscle weakness of 
all limbs, mostly in upper limbs.  At the same time, the patient complained of dyspnea 
with lower limb swelling. 
 Because of the above symptoms the patient is hospitalized et neurological unit 
 During hospitalization are made several examinations: laboratory with normal 
findings. The creatine kinase level was elevated. Prostigmine test was positive after 
15 minutes with improvement the ptosis, diplopia and muscle weakness. 
Echocardiogram revealed mild dilated cardiomyopathy with reduced ejection fraction. 
Chest CT showed a well-encapsulated anterior mediastinal mass. Conciliar thoracic 
surgeon: set indication for surgery 
 Before the operation the patient was treated with corticosteroids, with inhibitors of 
acetylcholine esterase and plasma exchange on three occasions. 
 Performances improvement of clinical picture with the withdrawal of neurological 
symptoms. 
 Complete thymectomy is made and after the operation the patient is set on 
corticosteroid and immunosuppressive therapy (azathioprine) and pyridostigmine with 
recommended regular audits by the neurologist and surgeon. 
 Ambulatory before surgery was advised to make test serum present antibodies to 
acetylcholine receptors. Serum tests were positive for AChR-binding (12.0 nmol/l) 
and AChR – modulating ( 96% loss of AChR) antibodies.  
 
 
Results: the patient is with stable clinical picture of the disease and set regular therapy for 
Myasthenia gravis 
 
Comments and discussion: even though this patient is young, the subacute onset of severe 
generalized form of Myasthenia gravis as well as the presence of serum antibodies raises the 
suspicion of paraneoplastic Myasthenia gravis related to thymoma. The coexistence of 
myocarditis has increased the likelihood of the presence of thymoma. 
 
Second case: 
  Patient 76 year old, man 
 The first symptoms of disease have occurred in October 2011 with an intense dry 
cough 
 Because of the above symptoms the patient is hospitalized et internal unit.   
 During hospitalization are made several examinations: laboratory with normal 
findings, but the sedimentation was elevated. X ray chest showed expansion of 
anterior mediastinum and advised to make chest CT. Chest CT showed large 
anterior mediastinal mass with indistinct margins encasing the great vessels as 
well as pleural metastases.  Conciliar thoracic surgeon: set indication for surgery 
 
 He underwent subtotal resection of en invasive thymoma followed by radiation 
therapy.  
 
 Before surgery and 6 months later the patient had no neurological symptoms of 
Myasthenia gravis  
 
 Six months later, he came to neurologist with progressive dysphagia, dyspnea and 
proximal muscle weakness. Neurological examination demonstrated moderate 
weakness of m .orbicularis oculi, neck flexors and proximal limb muscles after 
performing tests of neuromuscular fatiguing.  
 
 Ambulatory before surgery was advised to make test serum present antibodies to 
acetylcholine receptors. Serum tests were positive for AChR-binding (4 nmmol/l) 
AChR – modulating (100% loss of AChR) and striational antibodies. 
 
 Repeat chest CT showed residual thymoma in anterior mediastinum encasing the 
great vessels as well as pleural metastases. Prostigmine test was positive after 15 
minutes with improvement in limb and neck strength, but swallowing and 
respiratory symptoms persisted.  
 
 The patient is set on corticosteroids, immunosuppressive therapy and 
physiostigmine with regular controls et neurologist and surgeon.  
 
 
Results: the patient is with stable clinical picture of the disease and set regular therapy for 
Myasthenia gravis. In the same time he is monitored by the surgeon and internist because of 
symptoms from local tumor invasiveness. 
  
 
 
Comments and discussion: However, in about 2% of cases, the first Myasthenia gravis  
symptoms develop after the initial treatment of thymoma. One – third of thymoma cases are 
diagnose during evaluation of chest symptoms such as cough or dyspnea.  
All autoantibodies can be present in patients with thymoma who have no signs or symptoms 
of Myasthenia gravis, and they do not necessarily indicate that Myasthenia gravis will 
develop later. In cases of malignant thymoma that fail initial therapy, however, the prognosis 
is guarded because of local complication of invasive tumor 
Chemotherapy has been shown to improve survival in metastatic thymoma. With invasive 
thymoma, symptoms of dysphagia and dyspnea may be attributed to damage to the phrenic or 
recurrent laryngeal nerves from tumor invasion, radiation or surgery rather than Myasthenia 
gravis. Because of that those symptoms may not respond to Myasthenia gravis therapies. 
     The relapse rate for encapsulated tumors is less than 5% but the relapse rate is much 
higher for invasive or more malignant tumors. Thymoma recurrence can be heralded by 
worsening of myasthenia or the appearance of other paraneoplastic phenomena.          
    Postoperative radiotherapy is used for invasive malignant thymoma or other incomplete 
resection. Radiotherapy alone in unresectable, widely invasive disease can produce local 
disease control with a 5 year survival rate of 45% to 50%.  
 
Conclusion: Thymomatous MG was considered to be more severe and refractory to 
treatment than MG without thymoma. This observation probably reflected the older age in 
these patients, or coincidence of other autoimmune conditions. 
Recent case series show no significant difference in long – term MG prognosis related to the 
presence of thymoma. Likely factors leading to this improvement in outcome are advances in 
diagnostic imaging that allow earlier detection of thymoma , improvements in thymectomy 
techniques , and better perioperative myasthenia management.  
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